Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 11.30 is 128% above its 5-year average of 4.97, near the high end of its 5-year range (2.39–11.30).
As of the fiscal period ended Tuesday, June 30, 2026. 39.62% above its 12-month average of 8.09.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 11.30.
CURRENT RATIO
11.30
CURRENT RATIO AVG TTM
8.09
CURRENT RATIO AVG 3Y
5.73
CURRENT RATIO AVG 5Y
4.97
CURRENT RATIO AVG 10Y
5.72
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+39.62%
CURRENT VS 3Y AVG
+97.30%
CURRENT VS 5Y AVG
+127.52%
CURRENT VS 10Y AVG
+97.64%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.75
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+201.36%
vs the sector median at left
X4 Pharmaceuticals, Inc.
Market Cap
$261.27M
Current Ratio
11.30
TTM Avg
8.09
3Y Avg
5.73
5Y Avg
4.97
Market Cap
$261.43M
Current Ratio
15.82
TTM Avg
24.04
3Y Avg
14.70
5Y Avg
12.06
Market Cap
$262.92M
Current Ratio
5.35
TTM Avg
2.41
3Y Avg
1.69
5Y Avg
2.06
Market Cap
$259.56M
Current Ratio
8.88
TTM Avg
8.27
3Y Avg
7.75
5Y Avg
6.94
Market Cap
$259.49M
Current Ratio
2.90
TTM Avg
4.46
3Y Avg
4.43
5Y Avg
4.81
Market Cap
$259.14M
Current Ratio
16.00
TTM Avg
13.11
3Y Avg
8.33
5Y Avg
7.81
Market Cap
$259.12M
Current Ratio
13.89
TTM Avg
8.37
3Y Avg
7.38
5Y Avg
15.00
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| X4 Pharmaceuticals, Inc. (XFOR) | $261.27M | 11.30 | 8.09 | 5.73 | 4.97 |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | 15.82 | 24.04 | 14.70 | 12.06 |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | 5.35 | 2.41 | 1.69 | 2.06 |
| OraSure Technologies, Inc. (OSUR)vs › | $259.56M | 8.88 | 8.27 | 7.75 | 6.94 |
| Treace Medical Concepts, Inc. (TMCI)vs › | $259.49M | 2.90 | 4.46 | 4.43 | 4.81 |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.14M | 16.00 | 13.11 | 8.33 | 7.81 |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $259.12M | 13.89 | 8.37 | 7.38 | 15.00 |
| Palisade Bio, Inc. (PALI)vs › | $258.63M | 24.26 | 16.09 | 10.56 | 7.83 |
| Scribe Therapeutics Inc. (SCTX)vs › | $264.25M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $265.78M | 4.50 | 8.35 | 6.79 | 6.91 |
Current Ratio
11.30
Quick Ratio
11.02
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 11.30 |
| 2026-03-31 | 10.18 |
| 2025-12-31 | 10.16 |
| 2025-09-30 | 5.65 |
| 2025-06-30 | 3.19 |
| 2025-03-31 | 3.70 |
| 2024-12-31 | 3.41 |
| 2024-09-30 | 4.89 |
| 2024-06-30 | 6.07 |
| 2024-03-31 | 3.71 |
| 2023-12-31 | 5.34 |
| 2023-09-30 | 5.81 |
| 2023-06-30 | 6.64 |
| 2023-03-31 | 5.04 |
| 2022-12-31 | 5.76 |
| 2022-09-30 | 2.99 |
| 2022-06-30 | 2.39 |
| 2022-03-31 | 4.73 |
| 2021-12-31 | 6.27 |
| 2021-09-30 | 6.10 |
| 2021-06-30 | 7.73 |
| 2021-03-31 | 8.18 |
| 2020-12-31 | 6.97 |
| 2020-09-30 | 7.13 |
| 2020-06-30 | 10.19 |
| 2020-03-31 | 15.34 |
| 2019-12-31 | 13.68 |
| 2019-09-30 | 9.57 |
| 2019-06-30 | 7.32 |
| 2019-03-31 | 1.59 |
| 2018-12-31 | 1.18 |
| 2018-09-30 | 5.08 |
| 2018-06-30 | 5.54 |
| 2018-03-31 | 7.37 |
| 2017-12-31 | 7.45 |
| 2017-09-30 | 2.51 |
| 2017-06-30 | 4.30 |
| 2017-03-31 | 0.43 |
| 2016-03-31 | 0.00 |
